Biontech Se Earnings

Biontech Se’s revenue fell -15.84% since last year same period to $1244.8Mn in the Q3 2024. On a quarterly growth basis, Biontech Se has generated 867.21% jump in its revenue since last 3-months.

Biontech Se’s net profit fell -56.74% since last year same period to $198.1Mn in the Q3 2024. On a quarterly growth basis, Biontech Se has generated 124.52% jump in its net profits since last 3-months.

Biontech Se’s net profit margin fell -48.6% since last year same period to 15.91% in the Q3 2024. On a quarterly growth basis, Biontech Se has generated 102.54% jump in its net profit margins since last 3-months.

Biontech Se’s earning per share (EPS) estimates for the current quarter stand at -1.7 - a 15.84% jump from last quarter’s estimates.

Biontech Se’s earning per share (EPS) estimates for the current year stand at -1.7.

Biontech Se’s earning per share (EPS) jumped 31.34% since last year same period to 0.88 in the Q3 2024. This indicates that the Biontech Se has generated 31.34% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biontech Se’s return on assets (ROA) stands at -0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biontech Se’s return on equity (ROE) stands at -0.02.